Evaluation of p16INK4a expression as a single marker to select patients with HPV-driven oropharyngeal cancers for treatment de-escalation.
Steffen WagnerElena-Sophie PriggeNora WuerdemannHenrike RederAyman BushnakShachi Jenny SharmaTheresa ObermuellerMagnus von Knebel-DoeberitzThomas DreyerStefan GattenlöhnerGregor WolfJörn Pons-KühnemannClaus WittekindtJens Peter KlußmannPublished in: British journal of cancer (2020)
p16INK4a as a single marker appears insufficient to indicate OPSCC patients suitable for treatment de-escalation.